Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Coming together for CNS therapies
December 2018
SHARING OPTIONS:

SAN DIEGO & BOSTON—A new research collaboration targeting small-molecule therapeutics is underway between Neurocrine Biosciences Inc. and Jnana Therapeutics Inc., with a focus on several targets for central nervous system disorders (CNS). The partners will apply Jnana's proprietary drug discovery platform against the solute carrier family of transporters and Neurocrine's R&D experience in CNS conditions in the search for new therapeutics. Per the agreement, the companies will work together for the identification of novel compounds, with Neurocrine assuming responsibility for further lead optimization and the development and commercialization of any therapies resulting from this work. In addition, Neurocrine is granting Jnana access to part of its compound library to enable screening for hits on a predetermined number of non-CNS targets. Jnana will receive an upfront payment and committed research funding, and stands to receive milestone payments and royalties as well.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.